Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 10/20 | 0.63 |
| ▸ | MMP2 | P08253 | 9/20 | 0.63 |
| ▸ | MMP8 | P22894 | 7/20 | 0.63 |
| ▸ | MMP13 | P45452 | 7/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | MMP3 | P08254 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4379822 | 1.00 | MMP9 (0.63) | MMP9MMP2MMP8MMP13LMNA | |
| SCHEMBL4390355 | 1.00 | MMP9 (0.63) | MMP9MMP2MMP8MMP13LMNA | |
| SCHEMBL4382583 | 1.00 | MMP9 (0.63) | MMP9MMP2MMP8MMP13LMNA | |
| SCHEMBL1641551 | 0.98 | MMP9 (0.61) | MMP9MMP2MMP8MMP13LMNA | |
| SCHEMBL918796 | 0.98 | LMNA (0.64) | MMP9MMP2MMP8MMP13LMNA | |
| SCHEMBL5450754 | 0.92 | MMP9 (0.67) | MMP9MMP2MMP8MMP13LMNA | |
| SCHEMBL468545 | 0.92 | MMP9 (0.67) | MMP9MMP2MMP8MMP13LMNA | |
| Butethal SCHEMBL44262 | 0.92 | LMNA (0.67) | MMP9MMP2MMP8MMP13LMNA | |
| Butethal SCHEMBL2718536 | 0.90 | LMNA (0.64) | MMP9MMP2MMP8MMP13LMNA | |
| SCHEMBL14788924 | 0.85 | LMNA (0.57) | MMP9MMP2MMP8MMP13LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 343 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200147076-A1 | PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | PLATFORM BRIGHTWORKS TWO, LTD. (US) | 2020-05-14 | — | — | US | claimed |
| US-20180296556-A1 | PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | PLATFORM BRIGHTWORKS TWO, LTD. (US) | 2018-10-18 | — | — | US | claimed |
| US-20170348303-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. | 2017-12-07 | — | — | US | claimed |
| US-20170172971-A1 | PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | PLATFORM BRIGHTWORKS TWO, LTD. (US) | 2017-06-22 | — | — | US | claimed |
| CN-103635179-A | Improved parenteral formulations of lipophilic pharmaceutical agents and methods of making and using the same | UNIV TEXAS | 2014-03-12 | — | — | CN | claimed |
| EP-2701684-A1 | IMPROVED PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | Board Of Regents, The University Of Texas System (US) | 2014-03-05 | — | — | EP | claimed |
| US-20140030322-A1 | PHARMACEUTICAL COMPOSITIONS | LOCL PHARMA, INC. | 2014-01-30 | — | — | US | claimed |
| WO-2012148799-A1 | IMPROVED PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-11-01 | — | — | WO | claimed |
| US-20120277249-A1 | PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | GREENJAY THERAPEUTICS, INC. | 2012-11-01 | — | — | US | claimed |
| US-20120201888-A1 | Pharmaceutical Compositions | CHARLESTON LABORATORIES, INC. (US) | 2012-08-09 | — | — | US | claimed |
| EP-2240022-A2 | PHARMACEUTICAL COMPOSITIONS | Charleston Laboratories, Inc. (US) | 2010-10-20 | — | — | EP | claimed |
| US-20100172916-A1 | SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | US | claimed |
| WO-2010054286-A2 | SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-05-14 | — | — | WO | claimed |
| US-20090220429-A1 | METHOD AND A SYSTEM FOR ASSESSING NEUROLOGICAL CONDITIONS | METIS CURA EHF (IS) | 2009-09-03 | — | — | US | claimed |
| WO-2009089494-A2 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. (US) | 2009-07-16 | — | — | WO | claimed |
| US-20090175939-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. (US) | 2009-07-09 | — | — | US | claimed |
| CN-101155548-A | Methods and systems for assessing neurological conditions | MENTIS CURA EHF (IS) | 2008-04-02 | — | — | CN | claimed |
| EP-1861003-A1 | A METHOD AND A SYSTEM FOR ASSESSING NEUROLOGICAL CONDITIONS | Mentis Cura ehf. (IS) | 2007-12-05 | — | — | EP | claimed |
| WO-2006094797-A1 | A METHOD AND A SYSTEM FOR ASSESSING NEUROLOGICAL CONDITIONS | MENTIS CURA EHF. (IS) | 2006-09-14 | — | — | WO | claimed |
| US-20250325494-A1 | COMPOSITION FOR ORGAN-SPECIFIC DELIVERY OF NUCLEIC ACID | THEMEDIUM THERAPEUTICS CO., LTD. (CN) | 2025-10-23 | — | — | US | disclosed |
| US-20250228788-A1 | COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-07-17 | — | — | US | disclosed |
| US-20250188013-A1 | LIPID COMPOUND AND USE THEREOF | THEMEDIUM THERAPEUTICS CO., LTD. (CN) | 2025-06-12 | — | — | US | disclosed |
| CN-119753151-A | Use of GSDMD in diagnosing pancreatic cancer | 中国人民解放军总医院第五医学中心 | 2025-04-04 | — | — | CN | disclosed |
| EP-3551182-B1 | TOPICAL PHARMACEUTICAL COMPOSITION CONTAINING PHENYTOIN AND A (CO -)AN ALGESIC FOR THE TREATMENT OF CHRONIC PAIN | TOPICAL INNOVATIONS B V (NL) | 2025-03-19 | — | — | EP | disclosed |
| CN-119630280-A | Compositions and methods for preventing, treating, inhibiting and/or eliminating phytopathogenic infestations and infections | 诺维信公司 | 2025-03-14 | — | — | CN | disclosed |
| WO-2025052001-A1 | METHODS AND COMPOSITIONS FOR IMPROVING IMMUNE RESPONSE | MNEMO THERAPEUTICS (FR) | 2025-03-13 | — | — | WO | disclosed |
| US-20250000800-A1 | METHODS OF PREPARING DOSAGE FORMS USING 3D PRINTING CONTAINING AMORPHOUS SOLID DISPERSIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-01-02 | — | — | US | disclosed |
| CN-119193847-A | Use of GSDMD in diagnosing pancreatic cancer | 中国人民解放军总医院第五医学中心 | 2024-12-27 | — | — | CN | disclosed |
| US-20240390272-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | RECODE THERAPEUTICS, INC. | 2024-11-28 | — | — | US | disclosed |
| US-20240374513-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | RECODE THERAPEUTICS, INC. | 2024-11-14 | — | — | US | disclosed |
| US-20240374511-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | RECODE THERAPEUTICS, INC. | 2024-11-14 | — | — | US | disclosed |
| US-20240374514-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | RECODE THERAPEUTICS, INC. | 2024-11-14 | — | — | US | disclosed |
| US-20240374512-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | RECODE THERAPEUTICS, INC. | 2024-11-14 | — | — | US | disclosed |
| EP-4456921-A2 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-11-06 | — | — | EP | disclosed |
| US-12133924-B2 | Compositions and methods for organ specific delivery of nucleic acids | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-11-05 | — | — | US | disclosed |
| US-12121610-B2 | Compositions and methods for targeted delivery to cells | RECODE THERAPEUTICS, INC. (US) | 2024-10-22 | — | — | US | disclosed |
| US-20240245620-A1 | COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-07-25 | — | — | US | disclosed |
| US-20240245618-A1 | COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-07-25 | — | — | US | disclosed |
| WO-2024151838-A1 | CO-CRYSTALS WITH THIN-FILM FREEZE-DRYING PROCESS TO ENHANCE DELIVERY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-07-18 | — | — | WO | disclosed |
| EP-4400491-A1 | NOVEL LIPIDS USED FOR NUCLEIC ACID DELIVERY AND LIPID NANOPARTICLE COMPOSITION | Themedium Therapeutics Co., Ltd (CN) | 2024-07-17 | — | — | EP | disclosed |
| EP-4393484-A1 | COMPOSITION FOR ORGAN-SPECIFIC DELIVERY OF NUCLEIC ACID | Themedium Therapeutics Co., Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
| EP-4393511-A1 | LIPID COMPOUND AND USE THEREOF | Themedium Therapeutics Co., Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
| US-20240207178-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-06-27 | — | — | US | disclosed |
| US-20240197641-A1 | COMPOSITIONS AND METHODS FOR TARGETED SYSTEMIC DELIVERY TO CELLS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-06-20 | — | — | US | disclosed |
| US-11988733-B2 | Cross-domain network based magnetic resonance imaging undersampling pattern optimization and reconstruction method | ZHEJIANG UNIVERSITY (CN) | 2024-05-21 | — | — | US | disclosed |
| US-20240148666-A1 | COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-05-09 | — | — | US | disclosed |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-04-30 | — | — | US | disclosed |
| US-20240125898-A1 | METHOD AND SYSTEM FOR TRAINING A MACHINE LEARNING PROCEDURE TO ANALYZE A RADAR SIGNAL | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2024-04-18 | — | — | US | disclosed |
| US-20240108639-A1 | COMPOSITIONS AND METHODS OF MAKING COCRYSTALS USING DIELECTRIC HEATING WITH DISPERSIVE AND DISTRIBUTIVE MIXING | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-04-04 | — | — | US | disclosed |
| WO-2024050132-A1 | SELF-POWERED LOAD SENSING CIRCUITRY FOR TOTAL KNEE REPLACEMENT | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-03-07 | — | — | WO | disclosed |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-03-05 | — | — | US | disclosed |
| EP-4313001-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-02-07 | — | — | EP | disclosed |
| EP-4312987-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | Recode Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| EP-4313004-A1 | COMPOSITIONS AND METHODS FOR TARGETED SYSTEMIC DELIVERY TO CELLS | Recode Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2024026412-A1 | THIN FILM FREEZING METHODS AND COMPOSITIONS FORMULATED FROM DISPERSED ACTIVE AGENTS | TFF PHARMACEUTICALS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| EP-4304562-A1 | METHODS TO PREPARE DRY POWDERS USING SUSPENSION BASED THIN FILM FREEZING | Board of Regents, The University of Texas System (US) | 2024-01-17 | — | — | EP | disclosed |
| CN-220136821-U | Continuous detection device of tile material resistance to compression for building construction | 中国建筑第七工程局有限公司 | 2023-12-05 | — | — | CN | disclosed |
| US-20230338411-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | RECODE THERAPEUTICS, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230338300-A1 | PHARMACEUTICAL COMPOSITION CONTAINING COCRYSTALS FOR ADDITIVE MANUFACTURING | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-10-26 | — | — | US | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| EP-4259143-A1 | COMPOSITIONS AND METHODS OF MAKING COCRYSTALS USING DIELECTRIC HEATING WITH DISPERSIVE AND DISTRIBUTIVE MIXING | Board of Regents, The University of Texas System (US) | 2023-10-18 | — | — | EP | disclosed |
| US-20230324486-A1 | CROSS-DOMAIN NETWORK BASED MAGNETIC RESONANCE IMAGING UNDERSAMPLING PATTERN OPTIMIZATION AND RECONSTRUCTION METHOD | ZHEJIANG UNIVERSITY (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230302138-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | RECODE THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-11766408-B2 | Compositions and methods for organ specific delivery of nucleic acids | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230293429-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | RECODE THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-11744812-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| CN-113759412-B | Method and device for acquiring beam shape and energy detection unit response characteristics | 上海联影医疗科技股份有限公司 | 2023-08-22 | — | — | CN | disclosed |
| US-20230218533-A1 | 3D LASER SINTERING PROCESSES FOR IMPROVED DRUG DELIVERY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-07-13 | — | — | US | disclosed |
| WO-2023129915-A2 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023124971-A1 | MAGNETIC RESONANCE IMAGING DOWN-SAMPLING AND RECONSTRUCTION METHOD BASED ON CROSS-DOMAIN NETWORK | 浙江大学 | 2023-07-06 | — | — | WO | disclosed |
| US-20230201143-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2023-06-29 | — | — | US | disclosed |
| WO-2023118074-A1 | COMPRESSIBLE AND FREE FLOWING CO-PROCESSED MESOPOROUS SILICA | UNIVERZA V LJUBLJANI (SI) | 2023-06-29 | — | — | WO | disclosed |
| US-20230190684-A1 | METHODS OF TREATING COVID-19 WITH A NICLOSAMIDE COMPOUND | FIRST WAVE BIO, INC. | 2023-06-22 | — | — | US | disclosed |
| EP-4196110-A1 | PHARMACEUTICAL COMPOSITION CONTAINING COCRYSTALS FOR ADDITIVE MANUFACTURING | Board of Regents, The University of Texas System (US) | 2023-06-21 | — | — | EP | disclosed |
| US-20230181532-A1 | GRANULES FOR 3D PRINTING TECHNOLOGY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230167181-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF MANUFACTURE USING THERMALLY CONDUCTIVE EXCIPIENTS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-06-01 | — | — | US | disclosed |
| WO-2023086832-A1 | METHODS OF PREPARING DOSAGE FORMS USING 3D PRINTING CONTAINING AMORPHOUS SOLID DISPERSIONS | BOARD OF REGENTS, THE UNIVERSITY OFTEXAS SYSTEM (US) | 2023-05-19 | — | — | WO | disclosed |
| US-11648210-B2 | Compositions and methods for organ specific delivery of nucleic acids | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-05-16 | — | — | US | disclosed |
| US-11648209-B2 | Compositions and methods for organ specific delivery of nucleic acids | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-05-16 | — | — | US | disclosed |
| EP-4164618-A1 | 3D LASER SINTERING PROCESSES FOR IMPROVED DRUG DELIVERY | Board of Regents, The University of Texas System (US) | 2023-04-19 | — | — | EP | disclosed |
| CN-114581550-B | Magnetic resonance imaging down-sampling and reconstruction method based on cross-domain network | 浙江大学 | 2023-04-07 | — | — | CN | disclosed |
| US-20230102999-A1 | DEUTERATED NICLOSAMIDE | FIRST WAVE BIO, INC. | 2023-03-30 | — | — | US | disclosed |
| EP-4153145-A1 | GRANULES FOR 3D PRINTING TECHNOLOGY | Board of Regents, The University of Texas System (US) | 2023-03-29 | — | — | EP | disclosed |
| US-11590085-B2 | Compositions and methods for organ specific delivery of nucleic acids | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-02-28 | — | — | US | disclosed |
| US-11564896-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20230026843-A1 | COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-01-26 | — | — | US | disclosed |
| CN-113069547-B | Application of Bap1 as tumor treatment target in preparation of drugs for preventing or treating tumors | 同济大学附属第一妇婴保健院 | 2023-01-24 | — | — | CN | disclosed |
| EP-4115665-A1 | PAGING AREA UPDATE | Sony Group Corporation (JP) | 2023-01-11 | — | — | EP | disclosed |
| US-20230001396-A1 | COMPOSITIONS AND METHODS FOR CONTROLLED DELIVERY AND PROTECTION OF THERAPEUTIC AGENTS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-01-05 | — | — | US | disclosed |
| US-20220387337-A1 | COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-12-08 | — | — | US | disclosed |
| US-11510880-B2 | Compositions and methods for organ specific delivery of nucleic acids | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-11-29 | — | — | US | disclosed |
| US-20220313611-A1 | METHODS TO PREPARE DRY POWDERS USING SUSPENSION BASED THIN FILM FREEZING | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-10-06 | — | — | US | disclosed |
| WO-2022204286-A1 | COMPOSITIONS AND METHODS FOR TARGETED SYSTEMIC DELIVERY TO CELLS | RECODE THERAPEUTICS, INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| WO-2022204219-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | RECODE THERAPEUTICS, INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| WO-2022204043-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-09-29 | — | — | WO | disclosed |
| EP-4058190-A1 | COMPOSITIONS AND METHODS FOR CONTROLLED DELIVERY AND PROTECTION OF THERAPEUTIC AGENTS | Board of Regents, The University of Texas System (US) | 2022-09-21 | — | — | EP | disclosed |
| WO-2022192729-A1 | METHODS TO PREPARE DRY POWDERS USING SUSPENSION BASED THIN FILM FREEZING | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-09-15 | — | — | WO | disclosed |
| EP-4045480-A1 | PHARMACEUTICAL FORMULATIONS | First Wave Bio, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| US-20220233460-A1 | COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-07-28 | — | — | US | disclosed |
| US-11369566-B2 | Controlled release antimicrobial compositions and methods for the treatment of otic disorders | ALK-ABELLÓ, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-20220184153-A1 | METHOD OF TREATING BOVINE MASTITIS | The State of Israel, Ministry of Agriculture&Rural Development, Agricltural Research Oganization(ARO (IL) | 2022-06-16 | — | — | US | disclosed |
| WO-2022125869-A1 | COMPOSITIONS AND METHODS OF MAKING COCRYSTALS USING DIELECTRIC HEATING WITH DISPERSIVE AND DISTRIBUTIVE MIXING | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-06-16 | — | — | WO | disclosed |
| CN-114581550-A | Magnetic resonance imaging down-sampling and reconstruction method based on cross-domain network | 浙江大学 | 2022-06-03 | — | — | CN | disclosed |
| WO-2022099041-A1 | AUTOMATIC MULTI-ATTACHMENT CHANGING STATION | GIARRITTA MARK JEFFERY (US) | 2022-05-12 | — | — | WO | disclosed |
| US-20220133637-A1 | COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-05-05 | — | — | US | disclosed |
| US-11304911-B2 | Compositions and methods for organ specific delivery of nucleic acids | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-04-19 | — | — | US | disclosed |
| US-20220105057-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-04-07 | — | — | US | disclosed |
| US-20220079897-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-03-17 | — | — | US | disclosed |
| WO-2022054060-A1 | USE OF UNICONAZOLE FOR POTENTIATING ABSCISIC ACID EFFECTS IN PLANTS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2022-03-17 | — | — | WO | disclosed |
| WO-2022036290-A1 | PHARMACEUTICAL COMPOSITION CONTAINING COCRYSTALS FOR ADDITIVE MANUFACTURING | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-02-17 | — | — | WO | disclosed |
| US-20220040096-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY INC (US) | 2022-02-10 | — | — | US | disclosed |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2022-02-10 | — | — | US | disclosed |
| US-11229609-B2 | Compositions and methods for organ specific delivery of nucleic acids | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-01-25 | — | — | US | disclosed |
| US-20220000812-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2022-01-06 | — | — | US | disclosed |
| US-20210401762-A1 | COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-12-30 | — | — | US | disclosed |
| US-20210401784-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSE | FIRST WAVE BIO, INC. | 2021-12-30 | — | — | US | disclosed |
| WO-2021252793-A1 | 3D LASER SINTERING PROCESSES FOR IMPROVED DRUG DELIVERY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-12-16 | — | — | WO | disclosed |
| WO-2021236581-A1 | GRANULES FOR 3D PRINTING TECHNOLOGY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-11-25 | — | — | WO | disclosed |
| WO-2021222163-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF MANUFACTURE USING THERMALLY CONDUCTIVE EXCIPIENTS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-11-04 | — | — | WO | disclosed |
| US-20210338671-A1 | COMPOSITIONS OF SURFACE-MODIFIED THERAPEUTICALLY ACTIVE PARTICLES BY ULTRA-RAPID FREEZING | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2021-11-04 | — | — | US | disclosed |
| US-11147799-B2 | Topical pharmaceutical composition containing phenytoin and a (co-) analgesic for the treatment of chronic pain | Keppel Hesselink, Jan Marius (NL) | 2021-10-19 | — | — | US | disclosed |
| WO-2021188564-A1 | METHODS OF TREATING COVID-19 WITH A NICLOSAMIDE COMPOUND | FIRST WAVE BIO, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| US-11123286-B2 | Auris formulations for treating otic diseases and conditions | OTONOMY, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-11123285-B2 | Auris formulations for treating OTIC diseases and conditions | OTONOMY, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| EP-3846857-A1 | COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS | The Board Of Regents Of The University Of Texas System (US) | 2021-07-14 | — | — | EP | disclosed |
| US-11045466-B2 | Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same | PLATFORM BRIGHTWORKS TWO, LTD. (US) | 2021-06-29 | — | — | US | disclosed |
| EP-3827260-A1 | COMPOSITIONS OF SURFACE-MODIFIED THERAPEUTICALLY ACTIVE PARTICLES BY ULTRA-RAPID FREEZING | Board of Regents, The University of Texas System (US) | 2021-06-02 | — | — | EP | disclosed |
| US-20210138069-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2021-05-13 | — | — | US | disclosed |
| US-20210129406-A1 | DRUG SOLVATES IN THERMAL PROCESSES TO MAKE SOLID DISPERSIONS AT LOWER PROCESSING TEMPERATURES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2021-05-06 | — | — | US | disclosed |
| WO-2021076922-A1 | PHARMACEUTICAL FORMULATIONS | FIRST WAVE BIO, INC. (US) | 2021-04-22 | — | — | WO | disclosed |
| US-20210114973-A1 | PHARMACEUTICAL FORMULATIONS | FIRST WAVE BIO, INC. | 2021-04-22 | — | — | US | disclosed |
| US-10980756-B1 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-10912746-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-10905666-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20200405643-A1 | DRUG COMPOSITIONS CONTAINING POROUS CARRIERS MADE BY THERMAL OR FUSION-BASED PROCESSES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2020-12-31 | — | — | US | disclosed |
| US-20200397907-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | OTONOMY, INC. | 2020-12-24 | — | — | US | disclosed |
| US-10849867-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| EP-2299979-B1 | CONTROLLED RELEASE ANTIMICROBIAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY INC (US) | 2020-11-25 | — | — | EP | disclosed |
| US-10821185-B2 | Triglyceride otic formulations and uses thereof | OTONOMY INC. (US) | 2020-11-03 | — | — | US | disclosed |
| US-10799468-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FIRST WAVE BIO, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-10772828-B2 | Controlled release antimicrobial compositions and methods for the treatment of otic disorders | OTONOMY, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10772854-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20200276140-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2020-09-03 | — | — | US | disclosed |
| US-20200268694-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2020-08-27 | — | — | US | disclosed |
| US-10751281-B2 | Auris formulations for treating otic diseases and conditions | OTONOMY, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-10744103-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FIRST WAVE BIO, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| US-20200230128-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. | 2020-07-23 | — | — | US | disclosed |
| US-20200230051-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY, INC. | 2020-07-23 | — | — | US | disclosed |
| US-20200206218-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. | 2020-07-02 | — | — | US | disclosed |
| US-20200206139-A1 | COMPOSITIONS FOR THE IMPROVED DELIVERY OF DRUGS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2020-07-02 | — | — | US | disclosed |
| EP-3238709-B1 | IMPROVED PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | PLATFORM BRIGHTWORKS TWO LTD (US) | 2020-07-01 | — | — | EP | disclosed |
| US-20200197340-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2020-06-25 | — | — | US | disclosed |
| US-20200197339-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2020-06-25 | — | — | US | disclosed |
| US-20200147012-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2020-05-14 | — | — | US | disclosed |
| US-20200147076-A1 | PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | PLATFORM BRIGHTWORKS TWO, LTD. (US) | 2020-05-14 | — | — | US | disclosed |
| US-20200147013-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2020-05-14 | — | — | US | disclosed |
| US-20200129502-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. | 2020-04-30 | — | — | US | disclosed |
| US-20200069649-A1 | TOPICAL PHARMACEUTICAL COMPOSITION CONTAINING PHENYTOIN AND A (CO -) ANALGESIC FOR THE TREATMENT OF CHRONIC PAIN | TOPICAL INNOVATIONS B.V. (NL) | 2020-03-05 | — | — | US | disclosed |
| US-10548890-B2 | Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same | PLATFORM BRIGHTWORKS TWO, LTD. (US) | 2020-02-04 | — | — | US | disclosed |
| WO-2020023614-A1 | COMPOSITIONS OF SURFACE-MODIFIED THERAPEUTICALLY ACTIVE PARTICLES BY ULTRA-RAPID FREEZING | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-01-30 | — | — | WO | disclosed |
| EP-3551182-A1 | TOPICAL PHARMACEUTICAL COMPOSITION CONTAINING PHENYTOIN AND A (CO -)AN ALGESIC FOR THE TREATMENT OF CHRONIC PAIN | TOPICAL INNOVATIONS B.V. (NL) | 2019-10-16 | — | — | EP | disclosed |
| US-20190307678-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2019-10-10 | — | — | US | disclosed |
| US-20190298670-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | MONTERESEARCH S.R.L. (IT) | 2019-10-03 | — | — | US | disclosed |
| US-10292951-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FIRST WAVE BIO, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| EP-3478269-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | Otonomy, Inc. (US) | 2019-05-08 | — | — | EP | disclosed |
| US-10272034-B2 | Auris formulations for treating otic diseases and conditions | OTONOMY, INC. (US) | 2019-04-30 | — | — | US | disclosed |
| CN-109689027-A | Triglycerides aural preparations and application thereof | 奥德纳米有限公司 | 2019-04-26 | — | — | CN | disclosed |
| CN-109562137-A | Methods and compositions for treating conditions associated with abnormal inflammatory responses | 第波生物公司 | 2019-04-02 | — | — | CN | disclosed |
| US-10232044-B2 | Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders | OTONOMY, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| WO-2019051437-A1 | COMPOSITIONS FOR THE IMPROVED DELIVERY OF DRUGS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-03-14 | — | — | WO | disclosed |
| WO-2019051440-A1 | DRUG COMPOSITIONS CONTAINING POROUS CARRIERS MADE BY THERMAL OR FUSION-BASED PROCESSES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-03-14 | — | — | WO | disclosed |
| US-20180344728-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. | 2018-12-06 | — | — | US | disclosed |
| US-20180333360-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING OR PREVENTING PAIN | CHARLESTON LABORATORIES, INC. | 2018-11-22 | — | — | US | disclosed |
| US-20180325892-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. | 2018-11-15 | — | — | US | disclosed |
| US-20180296556-A1 | PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | PLATFORM BRIGHTWORKS TWO, LTD. (US) | 2018-10-18 | — | — | US | disclosed |
| US-10064856-B2 | Pharmaceutical compositions | LOCAL PHARMA, INC. (US) | 2018-09-04 | — | — | US | disclosed |
| US-10028949-B2 | Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same | PLATFORM BRIGHTWORKS TWO, LTD. (US) | 2018-07-24 | — | — | US | disclosed |
| EP-3344274-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | First Wave Bio, Inc. (US) | 2018-07-11 | — | — | EP | disclosed |
| US-10016368-B2 | Pharmaceutical compositions for treating or preventing pain | LOCL PHARMA, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| WO-2018106108-A1 | TOPICAL PHARMACEUTICAL COMPOSITION CONTAINING PHENYTOIN AND A (CO -)AN ALGESIC FOR THE TREATMENT OF CHRONIC PAIN | KEPPEL HESSELING, Jan Marius (NL) | 2018-06-14 | — | — | WO | disclosed |
| US-20180161271-A1 | CONTROLLED RELEASE ANTIMICROBIAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | ALK-ABELLÓ, INC. | 2018-06-14 | — | — | US | disclosed |
| CN-104352429-B | For treating the controlled release antimicrobial compositions of otic conditions and method | 奥德纳米有限公司 | 2018-05-18 | — | — | CN | disclosed |
| CN-107970209-A | The improved parenteral formulation of lipophilic pharmaceutical agent and preparation and use its method | 普拉福姆五金器具第二有限公司 | 2018-05-01 | — | — | CN | disclosed |
| EP-3311667-A1 | PHARMACEUTICAL COMPOSITIONS | Charleston Laboratories, Inc. (US) | 2018-04-25 | — | — | EP | disclosed |
| US-9918934-B2 | Linker-based lecithin microemulsion delivery vehicles | ACOSTA ZARA EDGAR JOEL (CA) | 2018-03-20 | — | — | US | disclosed |
| US-9867778-B2 | Controlled release antimicrobial compositions and methods for the treatment of otic disorders | OTONOMY, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-20180000950-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | OTONOMY, INC. | 2018-01-04 | — | — | US | disclosed |
| WO-2018005830-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | OTONOMY, INC. (US) | 2018-01-04 | — | — | WO | disclosed |
| US-9855264-B2 | Pharmaceutical compositions | LOCL PHARMA, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| CN-103635179-B | Improved parenteral formulations of lipophilic pharmaceutical agents and methods of making and using the same | 普拉福姆五金器具第二有限公司 | 2017-12-29 | — | — | CN | disclosed |
| US-20170360772-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. | 2017-12-21 | — | — | US | disclosed |
| EP-2120871-B2 | LINKER-BASED LECITHIN MICROEMULSION DELIVERY VEHICLES | ACOSTA-ZARA EDGAR JOEL (CA) | 2017-12-20 | — | — | EP | disclosed |
| US-20170348303-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. | 2017-12-07 | — | — | US | disclosed |
| US-20170348305-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. | 2017-12-07 | — | — | US | disclosed |
| US-20170348304-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. | 2017-12-07 | — | — | US | disclosed |
| EP-3238709-A1 | IMPROVED PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | PLATFORM BRIGHTWORKS TWO, LTD. (US) | 2017-11-01 | — | — | EP | disclosed |
| US-9789104-B2 | Pharmaceutical compositions | LOCL PHARMA, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9789105-B2 | Pharmaceutical compositions | LOCL PHARMA, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| EP-2451274-B1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES INC (US) | 2017-10-04 | — | — | EP | disclosed |
| US-9775837-B2 | Pharmaceutical compositions | CHARLESTON LABORATORIES, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| CN-107072940-A | Ear preparation for treating cerumen hypersecretion | 奥德纳米有限公司 | 2017-08-18 | — | — | CN | disclosed |
| US-9724345-B2 | Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same | PLATFORM BRIGHTWORKS TWO, LTD. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20170216439-A1 | OTIC FORMULATIONS FOR THE TREATMENT OF CERUMINOSIS | ROSENTBLOOM LP | 2017-08-03 | — | — | US | disclosed |
| US-20170172971-A1 | PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | PLATFORM BRIGHTWORKS TWO, LTD. (US) | 2017-06-22 | — | — | US | disclosed |
| EP-2701684-B1 | IMPROVED PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | PLATFORM BRIGHTWORKS TWO LTD (US) | 2017-06-14 | — | — | EP | disclosed |
| EP-3174525-A1 | OTIC FORMULATIONS FOR THE TREATMENT OF CERUMINOSIS | Otonomy, Inc. (US) | 2017-06-07 | — | — | EP | disclosed |
| WO-2017066488-A1 | TREATING PAIN USING A COMPOSITION COMPRISING AN OPIOID AND AN ANTIEMETIC | CHARLESTON LABORATORIES, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| US-9603796-B2 | Controlled release antimicrobial compositions and methods for the treatment of otic disorders | OTONOMY, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| WO-2017040864-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | First Wave Biopharma (US) | 2017-03-09 | — | — | WO | disclosed |
| US-20170056347-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2017-03-02 | — | — | US | disclosed |
| US-20170049704-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING OR PREVENTING PAIN | CHARLESTON LABORATORIES, INC. | 2017-02-23 | — | — | US | disclosed |
| EP-3129028-A1 | PHARMACEUTICAL COMPOSITIONS | Charleston Laboratories, Inc. (US) | 2017-02-15 | — | — | EP | disclosed |
| CN-106413717-A | Pharmaceutical compositions | 查尔斯顿实验室公司 | 2017-02-15 | — | — | CN | disclosed |
| US-20160375015-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. | 2016-12-29 | — | — | US | disclosed |
| EP-2240022-B1 | Bilayered tablets comprising oxycodone and promethazine | CHARLESTON LABORATORIES INC (US) | 2016-12-28 | — | — | EP | disclosed |
| US-9526704-B2 | Pharmaceutical compositions for treating or preventing pain | LOCL PHARMA, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-20160346278-A1 | PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | GREENJAY THERAPEUTICS, INC. | 2016-12-01 | — | — | US | disclosed |
| US-9498444-B2 | Pharmaceutical compositions | LOCL PHARMA, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| EP-3090743-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING HEADACHE AND ELIMINATING NAUSEA | Charleston Laboratories, Inc. (US) | 2016-11-09 | — | — | EP | disclosed |
| US-20160317447-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING OR PREVENTING PAIN | CHARLESTON LABORATORIES, INC. | 2016-11-03 | — | — | US | disclosed |
| US-9433625-B2 | Pharmaceutical compositions for treating or preventing pain | LOCL PHARMA, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-20160243028-A1 | Auris Formulations for Treating Otic Diseases and Conditions | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2016-08-25 | — | — | US | disclosed |
| US-20160228357-A1 | Auris Formulations for Treating Otic Diseases and Conditions | OTONOMY, INC. | 2016-08-11 | — | — | US | disclosed |
| US-9387177-B2 | Pharmaceutical compositions | LOCL PHARMA, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-9364433-B2 | Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same | GREENJAY THERAPEUTICS, INC. | 2016-06-14 | — | — | US | disclosed |
| US-20160106755-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. | 2016-04-21 | — | — | US | disclosed |
| US-20160095902-A1 | Auris Formulations for Treating Otic Diseases and Conditions | OTONOMY, INC. | 2016-04-07 | — | — | US | disclosed |
| US-20160067179-A1 | CONTROLLED RELEASE ANTIMICROBIAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | ALK-ABELLÓ, INC. | 2016-03-10 | — | — | US | disclosed |
| US-20160051547-A1 | CONTROLLED RELEASE ANTIMICROBIAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | ALK-ABELLÓ, INC. | 2016-02-25 | — | — | US | disclosed |
| US-20160051474-A1 | PHARMACEUTICAL COMPOSITIONS | LOCL PHARMA, INC. | 2016-02-25 | — | — | US | disclosed |
| US-20160038594-A1 | CONTROLLED RELEASE ANTIMICROBIAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | ALK-ABELLÓ, INC. | 2016-02-11 | — | — | US | disclosed |
| WO-2016019000-A1 | OTIC FORMULATIONS FOR THE TREATMENT OF CERUMINOSIS | OTONOMY, INC. (US) | 2016-02-04 | — | — | WO | disclosed |
| US-9233068-B2 | Controlled release antimicrobial compositions and methods for the treatment of OTIC disorders | OTONOMY, INC. (US) | 2016-01-12 | — | — | US | disclosed |
| US-9226901-B2 | Pharmaceutical compositions | LOCL PHARMA, INC. (US) | 2016-01-05 | — | — | US | disclosed |
| CN-105194086-A | Traditional Chinese medicine composition for preventing bacterial hemorrhagic disease of megalobrama amblycephala | YANG CHENGSHENG | 2015-12-30 | — | — | CN | disclosed |
| US-9205048-B2 | Controlled release antimicrobial compositions and methods for the treatment of otic disorders | OTONOMY, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-9198867-B2 | Pharmaceutical compositions | CHARLESTON LABORATORIES, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150320685-A1 | PHARMACEUTICAL COMPOSITIONS | LOCL PHARMA, INC. | 2015-11-12 | — | — | US | disclosed |
| US-20150306040-A1 | PHARMACEUTICAL COMPOSITIONS | LOCL PHARMA, INC. | 2015-10-29 | — | — | US | disclosed |
| US-20150297525-A1 | PHARMACEUTICAL COMPOSITIONS | LOCL PHARMA, INC. | 2015-10-22 | — | — | US | disclosed |
| US-20150290211-A1 | PHARMACEUTICAL COMPOSITIONS | LOCL PHARMA, INC. | 2015-10-15 | — | — | US | disclosed |
| WO-2015157738-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. (US) | 2015-10-15 | — | — | WO | disclosed |
| CN-104922648-A | Traditional Chinese medicine composite for treating chicken diarrhea and preparation method thereof | SHANDONG ZHONGMU VETERINARY PHARMACEUTICAL CO LTD | 2015-09-23 | — | — | CN | disclosed |
| US-9132087-B2 | Auris formulations for treating otic diseases and conditions | OTONOMY, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| CN-104825968-A | Traditional Chinese medicine medicament for treating rhinitis and preparation method thereof | WANG JIANJUN | 2015-08-12 | — | — | CN | disclosed |
| US-9102636-B2 | Analgesic compounds, compositions, and uses thereof | GALLEON PHARMACEUTICALS, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20150150793-A1 | Controlled Release Antimicrobial Compositions and Methods for the Treatment of Otic Disorders | ALK-ABELLÓ, INC. | 2015-06-04 | — | — | US | disclosed |
| CN-104491864-A | Controlled Release Antimicrobial Compositions And Methods For The Treatment Of Otic Disorders | OTONOMY INC | 2015-04-08 | — | — | CN | disclosed |
| CN-104352429-A | Controlled release antimicrobial compositions and methods for the treatment of otic disorders | OTONOMY INC | 2015-02-18 | — | — | CN | disclosed |
| US-20140364510-A1 | CONTROLLED RELEASE AURAL PRESSURE MODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. | 2014-12-11 | — | — | US | disclosed |
| CN-102014957-B | Otic formulations for the treatment of otic diseases and conditions | OTONOMY INC | 2014-12-10 | — | — | CN | disclosed |
| EP-2120871-B1 | LINKER-BASED LECITHIN MICROEMULSION DELIVERY VEHICLES | ACOSTA-ZARA EDGAR JOEL (CA) | 2014-11-26 | — | — | EP | disclosed |
| US-20140308349-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. (US) | 2014-10-16 | — | — | US | disclosed |
| US-8846770-B2 | Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders | OTONOMY, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8728522-B2 | Pharmaceutical compositions for treating or preventing pain | CHARLESTON LABORATORIES, INC. (US) | 2014-05-20 | — | — | US | disclosed |
| CN-103635179-A | Improved parenteral formulations of lipophilic pharmaceutical agents and methods of making and using the same | UNIV TEXAS | 2014-03-12 | — | — | CN | disclosed |
| EP-2701684-A1 | IMPROVED PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | Board Of Regents, The University Of Texas System (US) | 2014-03-05 | — | — | EP | disclosed |
| CN-101636148-B | Linker-based lecithin microemulsion delivery vehicle | ACOSTA-ZARA EDGAR JOEL | 2014-02-26 | — | — | CN | disclosed |
| US-8648119-B2 | Controlled release immunomodulator compositions and methods for the treatment of otic disorders | OTONOMY, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-20140030322-A1 | PHARMACEUTICAL COMPOSITIONS | LOCL PHARMA, INC. | 2014-01-30 | — | — | US | disclosed |
| US-20130216609-A1 | Controlled Release Antimicrobial Compositions and Methods for the Treatment of Otic Disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130150410-A1 | Controlled Release Ion Channel Modulator Compositions and Methods for the Treatment of Otic Disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-06-13 | — | — | US | disclosed |
| EP-2593104-A2 | METHODS OF TREATING AND PREVENTING/REDUCING THE LIKELIHOOD OF MESIAL TEMPORAL LOBE EPILEPSY (TLE) | Müller, Prof. Dr., Wolfgang (DE) | 2013-05-22 | — | — | EP | disclosed |
| US-20130116210-A1 | CONTROLLED RELEASE ANTIMICROBIAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| WO-2013038153-A1 | 18F-LABELLED BARBITURATE COMPOUNDS FOR USE AS POSITRON EMISSION IMAGING AGENTS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2013-03-21 | — | — | WO | disclosed |
| US-8399018-B2 | Controlled release ion channel modulator compositions and methods for the treatment of otic disorders | OTONOMY, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| CN-101534809-B | Use of substituted 2-amino-1, 2,3, 4-tetrahydronaphthalenes for producing medicaments for the prophylaxis, alleviation and/or treatment of various types of pain | UCB PHARMA GMBH | 2013-03-13 | — | — | CN | disclosed |
| CN-1780611-B | Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer | PURDUE PHARMA LTD | 2013-01-30 | — | — | CN | disclosed |
| EP-2544542-A1 | ANALGESIC COMPOUNDS, COMPOSITIONS, AND USES THEREOF | Galleon Pharmaceuticals, Inc. (US) | 2013-01-16 | — | — | EP | disclosed |
| US-8349353-B2 | Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders | OTONOMY, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| CN-102858176-A | Analgesic compounds, compositions, and uses thereof | GALLEON PHARMACEUTICALS INC | 2013-01-02 | — | — | CN | disclosed |
| US-8318817-B2 | Controlled release antimicrobial compositions and methods for the treatment of otic disorders | OTONOMY, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| WO-2012148799-A1 | IMPROVED PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-11-01 | — | — | WO | disclosed |
| US-20120277249-A1 | PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | GREENJAY THERAPEUTICS, INC. | 2012-11-01 | — | — | US | disclosed |
| EP-2032128-B1 | USE OF SUBSTITUTED 2-AMINOTETRALINES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE PREVENTION, ALLEVIATION AND/OR TREATMENT OF VARIOUS TYPES OF PAIN | UCB PHARMA GMBH (DE) | 2012-08-15 | — | — | EP | disclosed |
| US-20120201888-A1 | Pharmaceutical Compositions | CHARLESTON LABORATORIES, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202860-A2 | Analgesic Compounds, Compositions and Uses Thereof | GALLEON PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| EP-2451274-A1 | PHARMACEUTICAL COMPOSITIONS | Charleston Laboratories Inc. (US) | 2012-05-16 | — | — | EP | disclosed |
| US-8124126-B2 | Pharmaceutical compositions | CHARLESTON LABORATORIES, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20110262539-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| WO-2011112602-A1 | ANALGESIC COMPOUNDS, COMPOSITIONS, AND USES THEREOF | GALLEON PHARMACEUTICALS, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
| US-20110224269-A1 | Analgesic Compounds, Compositions, and Uses Thereof | GALLEON PHARMACEUTICALS, INC. | 2011-09-15 | — | — | US | disclosed |
| CN-102112112-A | Controlled release antimicrobial compositions and methods for treating otic disorders | OTONOMY INC | 2011-06-29 | — | — | CN | disclosed |
| US-20110104281-A1 | METHOD FOR TREATING PAIN USING A SUBSTITUTED 2-AMINOTETRALIN COMPOUND | UCB PHARMA GMBH (DE) | 2011-05-05 | — | — | US | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| CN-102014957-A | Otic formulations for the treatment of otic diseases and conditions | OTONOMY INC | 2011-04-13 | — | — | CN | disclosed |
| EP-2299979-A2 | CONTROLLED RELEASE ANTIMICROBIAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | Otonomy, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009132050-A9 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY, INC. (US) | 2011-02-03 | — | — | WO | disclosed |
| EP-2278999-A2 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | Otonomy, Inc. (US) | 2011-02-02 | — | — | EP | disclosed |
| WO-2011011692-A2 | METHODS OF TREATING AND PREVENTING/REDUCING THE LIKELIHOOD OF MESIAL TEMPORAL LOBE EPILEPSY (TLE) | STC.UNM (US) | 2011-01-27 | — | — | WO | disclosed |
| WO-2011006012-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| EP-2240022-A2 | PHARMACEUTICAL COMPOSITIONS | Charleston Laboratories, Inc. (US) | 2010-10-20 | — | — | EP | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20100172916-A1 | SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | US | disclosed |
| CN-101730467-A | Treatment of neuropathic pain | NUON THERAPEUTICS INC | 2010-06-09 | — | — | CN | disclosed |
| WO-2010054286-A2 | SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| EP-2173167-A2 | TREATMENT OF NEUROPATHIC PAIN | Nuon Therapeutics, Inc. (US) | 2010-04-14 | — | — | EP | disclosed |
| US-20100036000-A1 | CONTROLLED RELEASE ANTIMICROBIAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| WO-2010011609-A2 | CONTROLLED RELEASE ANTIMICROBIAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| CN-101636148-A | Linker-based lecithin microemulsion delivery vehicle | JOEL ACOSTA-ZARA EDGAR | 2010-01-27 | — | — | CN | disclosed |
| US-20100015228-A1 | CONTROLLED RELEASE ION CHANNEL MODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100004225-A1 | CONTROLLED RELEASE AURAL PRESSURE MODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-20090324552-A1 | CONTROLLED RELEASE CYTOTOXIC AGENT COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| WO-2009151744-A1 | S-NITROSOMERCAPTO COMPOUNDS AND RELATED DERIVATIVES | GALLEON PHARMACEUTICALS, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20090306225-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| CN-101600436-A | Methods of inhibiting respiratory depression using positive allosteric AMPA receptor modulators | UNIV ALBERTA (CA) | 2009-12-09 | — | — | CN | disclosed |
| US-20090297533-A1 | CONTROLLED RELEASE IMMUNOMODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| EP-2120871-A1 | LINKER-BASED LECITHIN MICROEMULSION DELIVERY VEHICLES | Acosta-Zara, Edgar, Joel (CA) | 2009-11-25 | — | — | EP | disclosed |
| WO-2009132050-A2 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
| CN-101534809-A | Use of substituted 2-amino-1, 2, 3, 4-tetrahydronaphthalenes for producing medicaments for the prophylaxis, alleviation and/or treatment of various types of pain | SANOL ARZNEI SCHWARZ GMBH (DE) | 2009-09-16 | — | — | CN | disclosed |
| US-20090220429-A1 | METHOD AND A SYSTEM FOR ASSESSING NEUROLOGICAL CONDITIONS | METIS CURA EHF (IS) | 2009-09-03 | — | — | US | disclosed |
| WO-2009089494-A2 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| US-20090175939-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| CN-101421735-A | Method of constructing and using a reference tool to generate a discriminatory signal for indicating a medical condition of a subject | MENTIS CURA EHF (IS) | 2009-04-29 | — | — | CN | disclosed |
| EP-2032128-A1 | USE OF SUBSTITUTED 2-AMINOTETRALINES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE PREVENTION, ALLEVIATION AND/OR TREATMENT OF VARIOUS TYPES OF PAIN | SCHWARZ PHARMA AG (DE) | 2009-03-11 | — | — | EP | disclosed |
| US-20090054740-A1 | METHOD AND APPARATUS OF CONSTRUCTING AND USING A REFERENCE TOOL TO GENERATE A DISCRIMINATORY SIGNAL FOR INDICATING A MEDICAL CONDITION OF A SUBJECT | MENTIS CURA EHF (IS) | 2009-02-26 | — | — | US | disclosed |
| US-20090042987-A1 | TREATMENT OF NEUROPATHIC PAIN | NUON THERAPEUTICS INC. | 2009-02-12 | — | — | US | disclosed |
| WO-2009008997-A2 | TREATMENT OF NEUROPATHIC PAIN | NUON THERAPEUTICS, INC. (US) | 2009-01-15 | — | — | WO | disclosed |
| WO-2008070961-A1 | LINKER-BASED LECITHIN MICROEMULSION DELIVERY VEHICLES | ACOSTA-ZARA EDGAR JOEL (CA) | 2008-06-19 | — | — | WO | disclosed |
| US-20080139392-A1 | Linker-Based Lecithin Microemulsion Delivery Vehicles | ACOSTA-ZARA EDGAR JOEL | 2008-06-12 | — | — | US | disclosed |
| US-20080104001-A1 | ALGORITHM FOR ESTIMATION OF BINDING EQULIBRIA IN INCLUSION COMPLEXATION, HOST COMPOUNDS IDENTIFIED THEREBY AND COMPOSITIONS OF HOST COMPOUND AND PHARMACEUTICAL | BAXTER INTERNATIONAL INC. | 2008-05-01 | — | — | US | disclosed |
| CN-101155548-A | Methods and systems for assessing neurological conditions | MENTIS CURA EHF (IS) | 2008-04-02 | — | — | CN | disclosed |
| US-20080008748-A1 | METHOD FOR TREATING PAIN USING A SUBSTITUTED 2-AMINOTETRALIN COMPOUND | UCB PHARMA GMBH (DE) | 2008-01-10 | — | — | US | disclosed |
| WO-2007147556-A1 | USE OF SUBSTITUTED 2-AMINOTETRALINES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE PREVENTION, ALLEVIATION AND/OR TREATMENT OF VARIOUS TYPES OF PAIN | SCHWARZ PHARMA AG (DE) | 2007-12-27 | — | — | WO | disclosed |
| EP-1861003-A1 | A METHOD AND A SYSTEM FOR ASSESSING NEUROLOGICAL CONDITIONS | Mentis Cura ehf. (IS) | 2007-12-05 | — | — | EP | disclosed |
| WO-2007098957-A1 | METHOD AND APPARATUS OF CONSTRUCTING AND USING A REFERENCE TOOL TO GENERATE A DISCRIMINATORY SIGNAL FOR INDICATING A MEDICAL CONDITION OF A SUBJECT | MENTIS CURA EHF. (IS) | 2007-09-07 | — | — | WO | disclosed |
| EP-1830292-A1 | Method of constructing and using a reference tool to generate a discriminatory signal for indicating a medical condition of a subject | Mentis Cura ehf. (IS) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006094797-A1 | A METHOD AND A SYSTEM FOR ASSESSING NEUROLOGICAL CONDITIONS | MENTIS CURA EHF. (IS) | 2006-09-14 | — | — | WO | disclosed |
| CN-1780611-A | Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer | PURDUE PHARMA LTD (US) | 2006-05-31 | — | — | CN | disclosed |
| CN-1747722-A | Sugar-free oral transmucosal solid dosage forms and uses thereof | CEPHALON INC (US) | 2006-03-15 | — | — | CN | disclosed |
| EP-1235561-A2 | FAST DISSOLVING COMPOSITION WITH PROLONGED SWEET TASTE | Panacea Biotec Limited (IN) | 2002-09-04 | — | — | EP | disclosed |
| WO-2001039749-A2 | FAST DISSOLVING COMPOSITION WITH PROLONGED SWEET TASTE | PANACEA BIOTEC LIMITED (IN) | 2001-06-07 | — | — | WO | disclosed |
| WO-2000024358-A2 | SYNTHESIS AND USES OF THIOPENTONE ENANTIOMERS | THE UNIVERSITY OF SYDNEY (AU) | 2000-05-04 | — | — | WO | disclosed |
| CN-1050993-C | Medicine with anti-stress, preventing stress and promoting intelligence | I A KOMISSAROVA (RU) | 2000-04-05 | — | — | CN | disclosed |
| US-5968963-A | ADMINISTERING 1-(PHENYLMETHYL)-4-UNDECYL-5H-TETRAZOLE-5-IMINE TO PREVENT OR TREAT HYPERCHOLESTEROLEMIA | WARNER-LAMBERT COMPANY (US) | 1999-10-19 | — | — | US | disclosed |
| CN-1192696-A | Spironolactone and angiotensin 2 antagonist combination therapy for treatment of congestive heart failure | SEARLE & CO (US) | 1998-09-09 | — | — | CN | disclosed |
| EP-0769005-A2 | PLA 2? INHIBITORS AND THEIR USE FOR INHIBITION OF INTESTINAL CHOLESTEROL ABSORPTION | WARNER-LAMBERT COMPANY (US) | 1997-04-23 | — | — | EP | disclosed |
| US-5578639-A | ANTICHOLESTEROL AGENTS | WARNER-LAMBERT COMPANY (US) | 1996-11-26 | — | — | US | disclosed |
| WO-1996001253-A2 | PLA2 INHIBITORS AND THEIR USE FOR INHIBITION OF INTESTINAL CHOLESTEROL ABSORPTION | WARNER-LAMBERT COMPANY (US) | 1996-01-18 | — | — | WO | disclosed |
| CN-1076854-A | Medicine with anti-stress, preventing stress and promoting intelligence | A E DOBRATVOLASKI (SU) | 1993-10-06 | — | — | CN | disclosed |
| CN-1075631-A | Medicine with anti-stress, preventing stress and promoting intelligence | I A KOMISSAROVA (RU) | 1993-09-01 | — | — | CN | disclosed |
| CN-1074118-A | Medicine with anti-stress, preventing stress and promoting intelligence | ADVANCE KK (JP) | 1993-07-14 | — | — | CN | disclosed |
| CN-1074118-A | Medicine with anti-stress, preventing stress and promoting intelligence | ADVANCE KK (JP) | 1993-07-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240390272-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | CHMP4B, LIPA, NPC1L1 | MMP9 3687/4885MMP2 3670/4885MMP8 2083/4885 |
| US-20210401784-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSE | FH, CS, ECHS1 | MMP9 2211/4885MMP2 2613/4885MMP8 287/4885 |
| US-20210401762-A1 | COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS | POLRMT, FABP1, SNRPE | MMP9 3122/4885MMP2 3084/4885MMP8 2157/4885 |
| US-20110104281-A1 | METHOD FOR TREATING PAIN USING A SUBSTITUTED 2-AMINOTETRALIN COMPOUND | AADAT, MTPN, MYOF | MMP9 2491/4885MMP2 1297/4885MMP8 1317/4885 |
| US-11648209-B2 | Compositions and methods for organ specific delivery of nucleic acids | POLRMT, FABP1, SNRPE | MMP9 3122/4885MMP2 3084/4885MMP8 2157/4885 |
| US-11766408-B2 | Compositions and methods for organ specific delivery of nucleic acids | POLRMT, FABP1, SNRPE | MMP9 3122/4885MMP2 3084/4885MMP8 2157/4885 |
| US-20180000950-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | CETP, LIPA, APOB | MMP9 3129/4885MMP2 2730/4885MMP8 3857/4885 |
| US-20200147012-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | MMP9 2078/4885MMP2 2549/4885MMP8 289/4885 |
| US-20130150410-A1 | Controlled Release Ion Channel Modulator Compositions and Methods for the Treatment of Otic Disorders | TRPV1, ATP2A1, TRPM2 | MMP9 3875/4885MMP2 3650/4885MMP8 4471/4885 |
| US-20200197339-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | MMP9 2114/4885MMP2 2537/4885MMP8 287/4885 |
| US-20100015228-A1 | CONTROLLED RELEASE ION CHANNEL MODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | TRPV1, ATP2A1, TRPM2 | MMP9 3875/4885MMP2 3650/4885MMP8 4471/4885 |
| US-20210138069-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | CETP, LIPA, APOB | MMP9 3956/4885MMP2 3093/4885MMP8 4176/4885 |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | MMP9 2078/4885MMP2 2549/4885MMP8 289/4885 |
| US-20200268694-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | MMP9 2114/4885MMP2 2537/4885MMP8 287/4885 |
| US-20230001396-A1 | COMPOSITIONS AND METHODS FOR CONTROLLED DELIVERY AND PROTECTION OF THERAPEUTIC AGENTS | LITAF, MIF, MB | MMP9 882/4885MMP2 1709/4885MMP8 884/4885 |
| US-12133924-B2 | Compositions and methods for organ specific delivery of nucleic acids | POLRMT, FABP1, SNRPE | MMP9 3122/4885MMP2 3084/4885MMP8 2157/4885 |
| US-20240374512-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | CHMP4B, LIPA, NPC1L1 | MMP9 3687/4885MMP2 3670/4885MMP8 2083/4885 |
| US-20230302138-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | CHMP4B, LIPA, NPC1L1 | MMP9 3687/4885MMP2 3670/4885MMP8 2083/4885 |
| US-20210114973-A1 | PHARMACEUTICAL FORMULATIONS | NCSTN, CACNA1B, CACNA1A | MMP9 2470/4885MMP2 2254/4885MMP8 2394/4885 |
| US-20150150793-A1 | Controlled Release Antimicrobial Compositions and Methods for the Treatment of Otic Disorders | OTC, OAT, MYOC | MMP9 2193/4885MMP2 1337/4885MMP8 562/4885 |
| US-10232044-B2 | Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders | OTC, MYOC, SLC26A4 | MMP9 1858/4885MMP2 1441/4885MMP8 1764/4885 |
| US-20160243028-A1 | Auris Formulations for Treating Otic Diseases and Conditions | OTC, AQP4, SLC26A4 | MMP9 1690/4885MMP2 1635/4885MMP8 582/4885 |
| US-20220040096-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | MMP9 1690/4885MMP2 1635/4885MMP8 582/4885 |
| US-10744103-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FH, CS, ECHS1 | MMP9 2078/4885MMP2 2549/4885MMP8 289/4885 |
| US-20240374514-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | CHMP4B, LIPA, NPC1L1 | MMP9 3687/4885MMP2 3670/4885MMP8 2083/4885 |
| US-11123286-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | MMP9 1690/4885MMP2 1635/4885MMP8 582/4885 |
| US-20190298670-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | MMP9 2114/4885MMP2 2537/4885MMP8 287/4885 |
| US-10849867-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | MMP9 2211/4885MMP2 2613/4885MMP8 287/4885 |
| US-20240245618-A1 | COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS | POLRMT, FABP1, SNRPE | MMP9 3122/4885MMP2 3084/4885MMP8 2157/4885 |
| US-20190307678-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | MMP9 1690/4885MMP2 1635/4885MMP8 582/4885 |
| US-20200230051-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | MMP9 1690/4885MMP2 1635/4885MMP8 582/4885 |
| US-20230190684-A1 | METHODS OF TREATING COVID-19 WITH A NICLOSAMIDE COMPOUND | ACE2, ACE, MME | MMP9 2149/4885MMP2 2739/4885MMP8 1598/4885 |
| US-20200197340-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | MMP9 2078/4885MMP2 2549/4885MMP8 289/4885 |
| US-20240207178-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | CHMP4B, LIPA, NPC1L1 | MMP9 3687/4885MMP2 3670/4885MMP8 2083/4885 |
| US-10799468-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FH, CS, ECHS1 | MMP9 2114/4885MMP2 2537/4885MMP8 287/4885 |
| US-10751281-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | MMP9 1690/4885MMP2 1635/4885MMP8 582/4885 |
| US-11590085-B2 | Compositions and methods for organ specific delivery of nucleic acids | POLRMT, FABP1, SNRPE | MMP9 3122/4885MMP2 3084/4885MMP8 2157/4885 |
| US-10821185-B2 | Triglyceride otic formulations and uses thereof | CETP, LIPA, APOB | MMP9 3129/4885MMP2 2730/4885MMP8 3857/4885 |
| US-20130216609-A1 | Controlled Release Antimicrobial Compositions and Methods for the Treatment of Otic Disorders | OTC, OAT, MYOC | MMP9 2193/4885MMP2 1337/4885MMP8 562/4885 |
| US-10772828-B2 | Controlled release antimicrobial compositions and methods for the treatment of otic disorders | OTC, OAT, MYOC | MMP9 2193/4885MMP2 1337/4885MMP8 562/4885 |
| US-20240374513-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | CHMP4B, LIPA, NPC1L1 | MMP9 3687/4885MMP2 3670/4885MMP8 2083/4885 |
| US-20100172916-A1 | SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS | MC1R, TYR, MITF | MMP9 2841/4885MMP2 2895/4885MMP8 2073/4885 |
| US-11229609-B2 | Compositions and methods for organ specific delivery of nucleic acids | POLRMT, FABP1, SNRPE | MMP9 3122/4885MMP2 3084/4885MMP8 2157/4885 |
| US-20240245620-A1 | COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS | POLRMT, FABP1, SNRPE | MMP9 3122/4885MMP2 3084/4885MMP8 2157/4885 |
| US-20220233460-A1 | COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS | POLRMT, FABP1, SNRPE | MMP9 3122/4885MMP2 3084/4885MMP8 2157/4885 |
| US-20140364510-A1 | CONTROLLED RELEASE AURAL PRESSURE MODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTC, MYOC, SLC26A4 | MMP9 1858/4885MMP2 1441/4885MMP8 1764/4885 |
| US-10292951-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FH, CS, ECHS1 | MMP9 2114/4885MMP2 2537/4885MMP8 287/4885 |
| US-20090306225-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | MMP9 1690/4885MMP2 1635/4885MMP8 582/4885 |
| US-20220079897-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | MMP9 2576/4885MMP2 2874/4885MMP8 1812/4885 |
| US-11744812-B2 | Methods of treatment | ACE2, ACE, SI | MMP9 2576/4885MMP2 2874/4885MMP8 1812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.